Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7Pancreatic Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Patient Compliance 1Malignant Neoplasms of Digestive Organs 1Head and Neck Neoplasms 1Fruquintinib 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Fluorouracil 498Bevacizumab 476Oxaliplatin 450Leucovorin 442Irinotecan 408Cetuximab 318Capecitabine 317pembrolizumab 142Folfox protocol 128Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 82IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 47Standard of Care 45Neoadjuvant Therapy 45Magnetic Resonance Spectroscopy 44Biopsy 44Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 39Cyclophosphamide 39Surveys and Questionnaires 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × potassium oxonate × Clear all
NCT03448549 2020-03-06

SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

Peking University Cancer Hospital & Institute

Phase 3 Unknown
1,191 enrolled
Gastrointestinal

Patient Compliance, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡